Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Penumbra Inc (PEN)

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,035,938
  • Shares Outstanding, K 34,793
  • Annual Sales, $ 444,940 K
  • Annual Income, $ 6,600 K
  • 60-Month Beta 0.71
  • Price/Sales 11.41
  • Price/Cash Flow 205.52
  • Price/Book 11.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.18
  • Number of Estimates 3
  • High Estimate 0.21
  • Low Estimate 0.14
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.66 +12.42%
on 09/30/19
154.98 -5.22%
on 09/17/19
-2.11 (-1.42%)
since 09/13/19
3-Month
130.66 +12.42%
on 09/30/19
185.70 -20.90%
on 07/25/19
-25.84 (-14.96%)
since 07/15/19
52-Week
110.84 +32.52%
on 12/24/18
185.70 -20.90%
on 07/25/19
+10.74 (+7.89%)
since 10/15/18

Most Recent Stories

More News
Penumbra Enrolls First Patient for Study on Coronary Vessels

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

PEN : 146.89 (+1.49%)
SYK : 214.95 (+1.08%)
GWPH : 120.33 (+3.55%)
CNAT : 0.34 (unch)
Penumbra Announces First Patient Enrolled in Study of Mechanical Power Aspiration for Thrombus Removal in Coronary Vessels

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S. study to...

PEN : 146.89 (+1.49%)
S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes...

SIGI : 74.31 (+0.20%)
RGEN : 79.22 (+2.55%)
FCFS : 90.78 (-0.08%)
SIG : 15.75 (+1.81%)
RRC : 3.50 (+0.86%)
TUP : 15.63 (-0.82%)
MIK : 9.57 (unch)
QEP : 2.94 (+1.38%)
VAL : 5.45 (+1.68%)
MDR : 2.20 (+2.80%)
ETSY : 60.02 (+1.54%)
PPC : 30.27 (-0.07%)
KAR : 23.86 (+0.93%)
AM : 7.45 (+0.54%)
OC : 62.94 (+3.23%)
PEN : 146.89 (+1.49%)
HCC : 21.76 (-0.05%)
CADE : 17.43 (+2.47%)
GCP : 20.01 (+1.32%)
CARS : 10.40 (+0.78%)
MNK : 2.08 (+0.48%)
KIRK : 1.41 (+2.92%)
NLS : 1.25 (+0.81%)
LKSD : 1.10 (-1.79%)
ASNA : 0.51 (+26.24%)
SUP : 2.80 (+3.70%)
SPN : 0.15 (-23.10%)
KOPN : 0.57 (-1.76%)
SPGI : 253.45 (+0.83%)
Sri Kosaraju Promoted to President and CFO of Penumbra

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the promotion of Sri Kosaraju to President, in addition to his current responsibilities as CFO of...

PEN : 146.89 (+1.49%)
Penumbra, Inc. to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY on Tuesday, September 10, 2019....

PEN : 146.89 (+1.49%)
Penumbra, Inc. to Present at the 2019 Wells Fargo Healthcare Conference

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 2019 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4, 2019.

WFC : 50.11 (+1.70%)
PEN : 146.89 (+1.49%)
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 28.57% and 2.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

PEN : 146.89 (+1.49%)
Penumbra: 2Q Earnings Snapshot

ALAMEDA, Calif. (AP) _ Penumbra Inc. (PEN) on Tuesday reported second-quarter profit of $16.6 million.

PEN : 146.89 (+1.49%)
Penumbra, Inc. Reports Second Quarter 2019 Financial Results

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2019.

PEN : 146.89 (+1.49%)
Stocks Advance in July Despite Rate Cut Selloff

Stocks Advance in July Despite Rate Cut Selloff

WSC : 15.62 (+0.39%)
SKX : 36.69 (+0.05%)
BIIB : 226.06 (+0.13%)
CACI : 229.13 (+0.50%)
LOGI : 40.78 (-0.12%)
WAB : 67.78 (+1.68%)
PEN : 146.89 (+1.49%)
ENPH : 24.14 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade PEN with:

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

2nd Resistance Point 149.04
1st Resistance Point 147.96
Last Price 146.89
1st Support Level 144.99
2nd Support Level 143.10

See More

52-Week High 185.70
Fibonacci 61.8% 157.10
Fibonacci 50% 148.27
Last Price 146.89
Fibonacci 38.2% 139.44
52-Week Low 110.84

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar